JP2015083010A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015083010A5 JP2015083010A5 JP2014255753A JP2014255753A JP2015083010A5 JP 2015083010 A5 JP2015083010 A5 JP 2015083010A5 JP 2014255753 A JP2014255753 A JP 2014255753A JP 2014255753 A JP2014255753 A JP 2014255753A JP 2015083010 A5 JP2015083010 A5 JP 2015083010A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- amino acid
- variable region
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 17
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 17
- 108091035707 Consensus sequence Proteins 0.000 claims 6
- 210000004443 dendritic cell Anatomy 0.000 claims 4
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 3
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 claims 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 2
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 101800001271 Surface protein Proteins 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000002919 epithelial cell Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 1
- 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101001018034 Homo sapiens Lymphocyte antigen 75 Proteins 0.000 claims 1
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims 1
- 108010010995 MART-1 Antigen Proteins 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100037686 Protein SSX2 Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 102000003425 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 102000040856 WT1 Human genes 0.000 claims 1
- 108700020467 WT1 Proteins 0.000 claims 1
- 101150084041 WT1 gene Proteins 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000030741 antigen processing and presentation Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US225307P | 2007-11-07 | 2007-11-07 | |
| US61/002,253 | 2007-11-07 | ||
| US19155108P | 2008-09-10 | 2008-09-10 | |
| US61/191,551 | 2008-09-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532344A Division JP5701606B2 (ja) | 2007-11-07 | 2008-11-07 | ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016137221A Division JP2017014218A (ja) | 2007-11-07 | 2016-07-12 | ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015083010A JP2015083010A (ja) | 2015-04-30 |
| JP2015083010A5 true JP2015083010A5 (cg-RX-API-DMAC7.html) | 2015-11-12 |
| JP6067667B2 JP6067667B2 (ja) | 2017-01-25 |
Family
ID=40257038
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532344A Expired - Fee Related JP5701606B2 (ja) | 2007-11-07 | 2008-11-07 | ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体 |
| JP2014255753A Expired - Fee Related JP6067667B2 (ja) | 2007-11-07 | 2014-12-18 | ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体 |
| JP2016137221A Pending JP2017014218A (ja) | 2007-11-07 | 2016-07-12 | ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532344A Expired - Fee Related JP5701606B2 (ja) | 2007-11-07 | 2008-11-07 | ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016137221A Pending JP2017014218A (ja) | 2007-11-07 | 2016-07-12 | ヒト樹状細胞および上皮細胞２０５（ｄｅｃ−２０５）に結合する抗体 |
Country Status (17)
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2933334B1 (en) | 2003-02-18 | 2019-09-18 | Baylor College of Medicine | Induced activation in dendritic cells |
| WO2006069198A1 (en) | 2004-12-22 | 2006-06-29 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
| EP2465510B1 (en) * | 2006-10-19 | 2018-11-28 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof |
| NZ578696A (en) * | 2007-02-02 | 2012-01-12 | Baylor Res Inst | Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells |
| WO2008104803A2 (en) | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
| CA2704583A1 (en) | 2007-11-07 | 2009-05-14 | Celldex Therapeutics Inc. | Antibodies that bind human dendritic and epithelial cell 205 receptor(dec-205) |
| PT2320948E (pt) | 2008-08-01 | 2013-06-17 | Cleveland Clinic Foundation | Métodos para o tratamento de lesões por reperfusão |
| EP3238739B1 (en) | 2008-09-22 | 2020-10-21 | Baylor College of Medicine | Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters |
| WO2011025964A2 (en) | 2009-08-29 | 2011-03-03 | Abbott Laboratories | Therapeutic dll4 binding proteins |
| EP2477655A4 (en) * | 2009-09-14 | 2014-02-12 | Baylor Res Inst | VACCINES TREATED ON LANGERHANS CELLS |
| CA2813494A1 (en) * | 2009-10-08 | 2011-04-14 | President And Fellows Of Harvard College | Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences |
| CA2781248A1 (en) * | 2009-11-18 | 2011-05-26 | Mannkind Corporation | Monoclonal antibodies and diagnostic uses thereof |
| BR112012021941A2 (pt) * | 2010-03-02 | 2022-02-01 | Abbvie Inc | Proteínas terapêuticas de ligação a dll4 |
| US9169325B2 (en) | 2010-04-13 | 2015-10-27 | Celldex Therapeutics, Inc. | Antibodies that bind human CD27 and uses thereof |
| EP2558109A4 (en) * | 2010-04-16 | 2014-09-24 | Bellicum Pharmaceuticals Inc | METHOD FOR TREATING HARD TUMORS |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| DE102010039019B4 (de) | 2010-08-06 | 2014-08-07 | Technische Universität Dresden | Antikörper gegen 6-sulfo LacNAc positive humane dendritische Zellen und deren Verwendung |
| RU2013110889A (ru) * | 2010-08-13 | 2014-09-20 | Бейлор Рисёч Инститьют | Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки |
| US10525168B2 (en) | 2010-10-20 | 2020-01-07 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications |
| US11484627B2 (en) | 2010-10-20 | 2022-11-01 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications |
| US11291483B2 (en) | 2010-10-20 | 2022-04-05 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants |
| US11207109B2 (en) | 2010-10-20 | 2021-12-28 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications |
| US20130295091A1 (en) * | 2011-01-10 | 2013-11-07 | University Of Zurich | Combination therapy including tumor associated antigen binding antibodies |
| EP2663367A4 (en) * | 2011-01-10 | 2014-08-06 | Cleveland Biolabs Inc | USE OF GREAT-SIMILAR RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER |
| WO2013009841A1 (en) * | 2011-07-11 | 2013-01-17 | Baylor Research Institute | Subsets of antigen-presenting cells (apc's) in the human vagina and their distinct functions |
| KR20140054140A (ko) * | 2011-07-27 | 2014-05-08 | 베일러 리서치 인스티튜트 | 췌장암에 대한 수지상 세포(ｄｃ) - 백신 치료요법 |
| EP3246339B1 (en) * | 2012-03-28 | 2019-10-09 | Sanofi | Antibodies to bradykinin b1 receptor ligands |
| GB201220010D0 (en) * | 2012-11-07 | 2012-12-19 | Oxford Biotherapeutics Ltd | Therapeutic amd diagnostic target |
| CN103044552B (zh) * | 2012-12-11 | 2019-01-29 | 中国医学科学院病原生物学研究所 | 人源化的抗树突状细胞表面dec-205分子的单克隆抗体 |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| SG11201506974XA (en) | 2013-03-14 | 2015-10-29 | Bellicum Pharmaceuticals Inc | Methods for controlling t cell proliferation |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| CA2912172A1 (en) | 2013-06-05 | 2014-12-11 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| MX346878B (es) * | 2013-06-26 | 2017-03-28 | Univ Nac Autónoma De México | Nuevos anticuerpos monoclonales contra el receptor dec-205 de celulas dendriticas de pollo. |
| CN103409451A (zh) * | 2013-06-28 | 2013-11-27 | 扬州维克斯生物科技有限公司 | 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法 |
| CU24320B1 (es) * | 2013-10-11 | 2018-02-08 | Berlin Chemie Ag | Anticuerpos conjugados contra antígeno linfocitario 75 para el tratamiento del cáncer |
| CN106132423B (zh) | 2014-02-14 | 2020-07-31 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| EP3174893B1 (en) | 2014-07-30 | 2020-05-06 | Genome Protection, Inc. | Flagellin compositions and uses |
| EP3189148A4 (en) | 2014-09-02 | 2018-05-02 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides |
| WO2016109002A2 (en) | 2014-10-16 | 2016-07-07 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
| CA2966300C (en) | 2014-11-03 | 2023-07-11 | Mirjam H.M. Heemskerk | T cell receptors directed against bob1 and uses thereof |
| US20180044429A1 (en) | 2015-03-09 | 2018-02-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
| CN107056932B (zh) * | 2016-12-24 | 2021-04-09 | 深圳大学 | 一种氨基酸序列、含ova表位的融合蛋白及其制备方法和应用 |
| GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
| BR112019021520A2 (pt) | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune |
| EP3691692B8 (en) * | 2017-10-14 | 2021-05-26 | AbbVie Inc. | Anti-cd71 activatable antibody drug conjugates and methods of use thereof |
| US20200347138A1 (en) * | 2017-10-27 | 2020-11-05 | Indian Institute Of Science | Dendritic cells-targeting vaccine |
| KR20210011919A (ko) | 2018-04-17 | 2021-02-02 | 셀덱스 쎄라퓨틱스, 인크. | 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물 |
| GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| WO2019244973A1 (ja) * | 2018-06-20 | 2019-12-26 | 中外製薬株式会社 | 標的細胞に対する免疫反応を活性化する方法およびその組成物 |
| JP7396275B2 (ja) | 2018-06-29 | 2023-12-12 | 日本ゼオン株式会社 | 識別媒体、真正性判定方法、及び物品 |
| WO2020123444A1 (en) | 2018-12-11 | 2020-06-18 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
| EP3896085A4 (en) * | 2018-12-12 | 2022-11-30 | Shanghai Pharmaexplorer Co., Ltd. | MONOCLONAL ANTIBODY TO HUMAN INTERLEUKIN 5 (IL-5) AND ITS USE |
| JP2023503615A (ja) * | 2019-11-26 | 2023-01-31 | シーダーズ－サイナイ メディカル センター | 循環からミトコンドリアｄｎａ又はゲノムｄｎａを枯渇させることにより疾患及び症状を治療する組成物及び方法 |
| EP4069296A4 (en) * | 2019-12-05 | 2023-12-27 | DendroCyte BioTech Pty Ltd | ANTIGEN LOADING |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| MX2022010515A (es) | 2020-02-28 | 2022-11-14 | Tallac Therapeutics Inc | Conjugacion mediada por transglutaminasa. |
| AU2021300362A1 (en) | 2020-07-01 | 2023-02-23 | ARS Pharmaceuticals, Inc. | Anti-ASGR1 antibody conjugates and uses thereof |
| BR112023020303A2 (pt) | 2021-04-09 | 2023-11-14 | Celldex Therapeutics Inc | Anticorpos contra ilt4, anticorpo anti-ilt4/pd-l1 bispecífico e seus usos |
| CA3219316A1 (en) | 2021-05-26 | 2022-12-01 | Christian Rohlff | Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor |
| WO2023077521A1 (en) | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Anti-ilt4 and anti-pd-1 bispecific constructs |
| JP2024540451A (ja) | 2021-11-18 | 2024-10-31 | オックスフォード バイオセラピューティックス リミテッド | 組合せ医薬 |
| CN115028741A (zh) * | 2022-06-21 | 2022-09-09 | 苏州工业园区唯可达生物科技有限公司 | 一种肿瘤抗原抗体复合物及制备方法和应用 |
| CN114887047A (zh) * | 2022-06-21 | 2022-08-12 | 苏州工业园区唯可达生物科技有限公司 | 基于ny-eso-1肿瘤抗原的疫苗及制备方法 |
| CN114989311A (zh) * | 2022-06-21 | 2022-09-02 | 苏州工业园区唯可达生物科技有限公司 | 3g9-lnm抗体偶联蛋白及其制备方法和应用 |
| CN114949191A (zh) * | 2022-06-21 | 2022-08-30 | 苏州工业园区唯可达生物科技有限公司 | 一种肿瘤疫苗及其制备方法 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2857090A (en) * | 1955-06-02 | 1958-10-21 | Crown Zellerbach Corp | Container for heavy articles |
| US2887389A (en) * | 1955-06-03 | 1959-05-19 | Creath Q Linville | Cartons |
| US3164316A (en) * | 1962-05-21 | 1965-01-05 | Weyerhaeuser Co | Carton |
| US3353740A (en) * | 1965-12-28 | 1967-11-21 | Int Paper Co | Reclosable carton |
| US3447735A (en) * | 1967-07-03 | 1969-06-03 | Western Kraft Corp | Easy-opening container |
| US3552633A (en) * | 1969-10-27 | 1971-01-05 | Inland Container Corp | Pallet case |
| US3698548A (en) * | 1970-06-15 | 1972-10-17 | Robert N Stenzel | Box for dispensing flexible sheet material |
| US3883067A (en) * | 1972-12-15 | 1975-05-13 | Continental Can Co | Carton corner construction |
| US4267959A (en) * | 1979-10-22 | 1981-05-19 | Westvaco Corporation | Hinged paperboard container |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US4954617A (en) * | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| EP0318554B2 (en) * | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| DE318216T1 (de) | 1987-11-18 | 1990-06-13 | Chiron Corp., Emeryville, Calif. | Nanbv-diagnostika und vakzine. |
| US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| ATE149841T1 (de) * | 1990-01-26 | 1997-03-15 | Immunomedics Inc | Impfstoffe gegen krebs und infektionskrankheiten |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1992007579A1 (en) | 1990-11-06 | 1992-05-14 | The Children's Medical Center Corporation | Soluble mannose receptor peptides |
| US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| EP0593592B1 (en) | 1991-07-08 | 1998-03-25 | The University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
| DE4123760C2 (de) | 1991-07-18 | 2000-01-20 | Dade Behring Marburg Gmbh | Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2 |
| GB9117522D0 (en) | 1991-08-14 | 1991-10-02 | Medical Res Council | Ligands for dendritic cells, their uses and production |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| US5620886A (en) | 1993-03-18 | 1997-04-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1995012409A1 (en) * | 1993-11-04 | 1995-05-11 | Canterbury Health Limited | Dendritic cell-specific antibodies and methods for their preparation |
| WO1995015340A1 (en) | 1993-12-03 | 1995-06-08 | The Board Of Trustees Of Leland Stanford Junior University | Monoclonal antibodies to antigens expressed by human dendritic cells |
| US5541110A (en) * | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
| EP1167378B1 (en) | 1994-07-15 | 2011-05-11 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US5698679A (en) * | 1994-09-19 | 1997-12-16 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
| US20040258688A1 (en) * | 1995-01-31 | 2004-12-23 | Daniel Hawiger | Enhanced antigen delivery and modulation of the immune response therefrom |
| US20020187131A1 (en) * | 1995-01-31 | 2002-12-12 | Daniel Hawiger | Enhanced antigen delivery and modulation of the immune response therefrom |
| CA2211993A1 (en) | 1995-01-31 | 1996-08-08 | The Rockefeller University | Identification of dec, (dentritic and epithelial cells, 205 kda), a receptor with c-type lectin domains, nucleic acids encoding dec, and uses thereof |
| US5840306A (en) | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
| US5869057A (en) * | 1995-06-07 | 1999-02-09 | Rock; Edwin P. | Recombinant vaccines to break self-tolerance |
| US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
| US6117977A (en) * | 1996-04-24 | 2000-09-12 | Genentech, Inc. | Type C lectins |
| US6432666B1 (en) * | 1996-05-29 | 2002-08-13 | The Corporation Of The Trustees Of The Sisters Of Mercy In Queensland | Dendritic cell receptor |
| US5922845A (en) * | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| US6069233A (en) | 1996-10-03 | 2000-05-30 | Memorial Sloan-Kettering Cancer Center | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| DE69731977T2 (de) * | 1996-10-09 | 2005-12-08 | Canterbury Health Ltd. | Spezifische antikörper für dendritische zellen |
| AU755279C (en) * | 1997-07-09 | 2004-02-19 | Schering Corporation | Isolated dendritic cell membrane protein genes |
| DE69840578D1 (de) | 1997-09-29 | 2009-04-02 | Macfarlane Burnet Inst For Med | Mannose-rezeptor tragende zellinie und antigen zusammensetzung |
| US6340569B1 (en) * | 1997-11-12 | 2002-01-22 | University Of Pittsburgh | Monoclonal antibody and antigens specific therefor and methods of using same |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| CA2323083A1 (en) | 1998-03-17 | 1999-09-23 | Schering Corporation | Isolated mammalian membrane protein genes and related reagents |
| TR200002930T2 (tr) | 1998-04-09 | 2000-12-21 | Smithkline Beecham Biologicals S.A. | Kolaylaştırıcı kompozisyonlar |
| EP1073464B1 (en) | 1998-04-28 | 2004-10-06 | Smithkline Beecham Corporation | Monoclonal antibodies with reduced immunogenicity |
| AU4039999A (en) | 1998-05-11 | 1999-11-29 | Micromet Ag | Antibodies to dendritic cells and human dendritic cell populations and uses thereof |
| WO2000000156A2 (en) | 1998-06-26 | 2000-01-06 | Trustees Of Dartmouth College | Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands |
| KR100295558B1 (ko) | 1998-06-27 | 2001-07-12 | 김기태 | 1차면역세포들중덴드리틱세포(dendriticcell)표면에특이하게작용하는단클론항체3-6-a |
| EP0997476A3 (en) | 1998-09-25 | 2000-07-19 | Schering-Plough | Antibodies to a mammalian Langerhans cell antigen and their uses |
| IL144636A0 (en) * | 1999-02-18 | 2002-05-23 | Hoffmann La Roche | Thioamide derivatives |
| EP1046651A1 (en) | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| US6774226B1 (en) | 1999-11-30 | 2004-08-10 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| AU2001255196A1 (en) | 2000-03-29 | 2001-10-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing immunogenicity of antigens |
| AU5532601A (en) | 2000-04-12 | 2001-10-30 | Univ Rochester | Targeted vaccine delivery systems |
| US7201714B2 (en) * | 2000-04-27 | 2007-04-10 | Graphic Packaging International, Inc. | Paperboard cartons with laminated reinforcing ribbons and method of printing same |
| CA2408594A1 (en) | 2000-05-08 | 2001-11-15 | Medarex, Inc. | Human monoclonal antibodies to dendritic cells |
| US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| GB0105360D0 (en) * | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
| US6794501B2 (en) | 2001-05-04 | 2004-09-21 | Ludwig Institute For Cancer Research | Colon cancer antigen panel |
| EP1451226A1 (en) * | 2001-11-30 | 2004-09-01 | Crucell Holland B.V. | Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
| US8029803B2 (en) * | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| US7541032B2 (en) | 2002-09-20 | 2009-06-02 | Stichting Katholieke Universiteit | Antigen uptake receptor for Candida albicans on dendritic cells |
| US20040146948A1 (en) * | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| WO2004074432A2 (en) * | 2003-01-31 | 2004-09-02 | Celldex Therapeutics, Inc. | Antibody vaccine conjugates and uses therefor |
| CA2517926A1 (en) * | 2003-03-04 | 2004-10-28 | Alexion Pharmaceuticals, Inc. | Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells |
| US6834793B2 (en) * | 2003-05-31 | 2004-12-28 | Graphic Packaging International, Inc. | Enclosed container carton convertible into a tray |
| AU2004266034B2 (en) * | 2003-08-21 | 2011-01-27 | Lipotek Pty Ltd | In vivo targeting of dendritic cells |
| JP4088655B2 (ja) * | 2004-09-06 | 2008-05-21 | キリンファーマ株式会社 | 抗ａ３３抗体 |
| CA2623406C (en) * | 2005-09-21 | 2011-11-15 | Graphic Packaging International, Inc. | Reinforced cartons |
| EA017812B1 (ru) * | 2005-12-08 | 2013-03-29 | Медарекс, Инк. | Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение |
| BRPI0620601A2 (pt) * | 2005-12-08 | 2011-11-16 | Medarex Inc | anticorpo monoclonal humano isolado ou uma porção ligante ao antìgeno do mesmo, composição, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-o8e e método para tratar ou prevenir uma doença definida pelo crescimento de células tumorais expressando o8e |
| CA2704583A1 (en) | 2007-11-07 | 2009-05-14 | Celldex Therapeutics Inc. | Antibodies that bind human dendritic and epithelial cell 205 receptor(dec-205) |
| JP6136343B2 (ja) | 2012-06-12 | 2017-05-31 | 株式会社リコー | 情報処理システム、情報処理方法、プログラム、及び記録媒体 |
| KR102264548B1 (ko) | 2014-11-21 | 2021-06-16 | 삼성전자주식회사 | 반도체 패키지 및 그 제조 방법 |
-
2008
- 2008-11-07 CA CA2704583A patent/CA2704583A1/en not_active Abandoned
- 2008-11-07 EA EA201692127A patent/EA201692127A1/ru unknown
- 2008-11-07 DK DK08848354.0T patent/DK2224954T3/en active
- 2008-11-07 MX MX2010005022A patent/MX2010005022A/es active IP Right Grant
- 2008-11-07 EP EP08848354.0A patent/EP2224954B1/en active Active
- 2008-11-07 KR KR1020167002430A patent/KR101811965B1/ko not_active Expired - Fee Related
- 2008-11-07 US US12/266,745 patent/US8236318B2/en not_active Expired - Fee Related
- 2008-11-07 WO PCT/US2008/082745 patent/WO2009061996A2/en not_active Ceased
- 2008-11-07 CN CN200880119337.7A patent/CN101888856B/zh not_active Expired - Fee Related
- 2008-11-07 SG SG10201605208QA patent/SG10201605208QA/en unknown
- 2008-11-07 JP JP2010532344A patent/JP5701606B2/ja not_active Expired - Fee Related
- 2008-11-07 EA EA201000770A patent/EA026990B1/ru not_active IP Right Cessation
- 2008-11-07 SG SG2013003413A patent/SG187482A1/en unknown
- 2008-11-07 AU AU2008323848A patent/AU2008323848B2/en not_active Ceased
- 2008-11-07 BR BRPI0820270-2A patent/BRPI0820270A2/pt not_active IP Right Cessation
- 2008-11-07 KR KR1020107012364A patent/KR101624751B1/ko not_active Expired - Fee Related
- 2008-11-07 NZ NZ585556A patent/NZ585556A/en not_active IP Right Cessation
- 2008-11-07 ES ES08848354.0T patent/ES2445755T3/es active Active
- 2008-11-07 EP EP12196330.0A patent/EP2570137A3/en not_active Withdrawn
- 2008-11-07 NZ NZ599777A patent/NZ599777A/xx not_active IP Right Cessation
-
2009
- 2009-05-05 US US12/387,654 patent/US8362214B2/en not_active Expired - Fee Related
-
2010
- 2010-04-28 IL IL205393A patent/IL205393A/en not_active IP Right Cessation
- 2010-05-04 ZA ZA2010/03101A patent/ZA201003101B/en unknown
-
2012
- 2012-07-06 US US13/542,909 patent/US8586720B2/en not_active Expired - Fee Related
- 2012-12-17 US US13/716,973 patent/US9624300B2/en not_active Expired - Fee Related
-
2014
- 2014-12-18 JP JP2014255753A patent/JP6067667B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-12 JP JP2016137221A patent/JP2017014218A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015083010A5 (cg-RX-API-DMAC7.html) | ||
| JP2017014218A5 (cg-RX-API-DMAC7.html) | ||
| JP7542870B2 (ja) | 免疫療法のためのナノ粒子組成物及び方法 | |
| Safarzadeh Kozani et al. | Nanobody-based CAR-T cells for cancer immunotherapy | |
| Schooten et al. | MAGE-A antigens as targets for cancer immunotherapy | |
| TWI828625B (zh) | 引導及導航控制蛋白質以及彼之製造及使用方法 | |
| JP2011503014A5 (cg-RX-API-DMAC7.html) | ||
| JP2021518103A5 (cg-RX-API-DMAC7.html) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2015535691A5 (cg-RX-API-DMAC7.html) | ||
| JP2013531970A5 (cg-RX-API-DMAC7.html) | ||
| JP2014039548A5 (cg-RX-API-DMAC7.html) | ||
| JP2019510733A5 (cg-RX-API-DMAC7.html) | ||
| HRP20171315T1 (hr) | Optimizacija humanih antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3), i njihove primjene | |
| Durham et al. | GITR ligand fusion protein agonist enhances the tumor antigen–specific CD8 T-cell response and leads to long-lasting memory | |
| JP2019512207A5 (cg-RX-API-DMAC7.html) | ||
| TW202003037A (zh) | 引導及導航控制蛋白及其製備和使用方法 | |
| JP2015535689A5 (cg-RX-API-DMAC7.html) | ||
| IL295398B1 (en) | Antibody/t-cell receptor chimeric constructs and uses thereof | |
| JP2019506865A (ja) | 改善された内部移行特性を有する多重特異性抗原結合分子 | |
| JPWO2019175218A5 (cg-RX-API-DMAC7.html) | ||
| TW201100096A (en) | Antigen presenting cell targeted anti-viral vaccines | |
| JP2018509163A5 (cg-RX-API-DMAC7.html) | ||
| JP2018506961A5 (cg-RX-API-DMAC7.html) | ||
| ES2820729T3 (es) | Redirectores de células T específicas de antígenos |